MX9703191A - Anticuerpos contra proteinas alogenicas y xenogenicas, su uso en diagnostico y terapia y metodos para la determinacion de los mismos. - Google Patents

Anticuerpos contra proteinas alogenicas y xenogenicas, su uso en diagnostico y terapia y metodos para la determinacion de los mismos.

Info

Publication number
MX9703191A
MX9703191A MX9703191A MX9703191A MX9703191A MX 9703191 A MX9703191 A MX 9703191A MX 9703191 A MX9703191 A MX 9703191A MX 9703191 A MX9703191 A MX 9703191A MX 9703191 A MX9703191 A MX 9703191A
Authority
MX
Mexico
Prior art keywords
diagnosis
therapy
methods
determination
antibodies against
Prior art date
Application number
MX9703191A
Other languages
English (en)
Other versions
MXPA97003191A (es
Inventor
Alberto Bartorelli
Original Assignee
Zetesis Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zetesis Spa filed Critical Zetesis Spa
Publication of MX9703191A publication Critical patent/MX9703191A/es
Publication of MXPA97003191A publication Critical patent/MXPA97003191A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732Antibody-dependent cellular cytotoxicity [ADCC]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734Complement-dependent cytotoxicity [CDC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Food Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invencion se relaciona con métodos de diagnostico para la deteccion de anticuerpos naturales que reconocen proteínas que se pueden extraer de organos de mamífero que tienen un peso molecular de aproximadamente 14 unidades Kda dotados con actividad antitumoral cuando se administran a especies xenogénicas.
MXPA/A/1997/003191A 1994-11-04 1997-04-30 Anticuerpos contra proteinas alogenicas yxenogenicas, su uso en diagnostico y terapia ymetodos para la determinacion de los mismos MXPA97003191A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IT94MI002238A IT1276860B1 (it) 1994-11-04 1994-11-04 Anticorpi naturali contro proteine allogeniche e xenogeniche e metodi per la loro determinazione
MIMI94A002238 1994-11-04
PCT/EP1995/004239 WO1996014340A1 (en) 1994-11-04 1995-10-30 Antibodies against allogenic and xenogenic proteins, their use in diagnosis and therapy and methods for the determination thereof

Publications (2)

Publication Number Publication Date
MX9703191A true MX9703191A (es) 1997-07-31
MXPA97003191A MXPA97003191A (es) 1997-12-01

Family

ID=

Also Published As

Publication number Publication date
PL181115B1 (pl) 2001-05-31
FI971879A7 (fi) 1997-06-24
CN1046737C (zh) 1999-11-24
AU3845395A (en) 1996-05-31
AR002243A1 (es) 1998-03-11
EP0789716B1 (en) 2000-04-26
NZ295171A (en) 1998-07-28
EP0789716A1 (en) 1997-08-20
PT789716E (pt) 2000-09-29
TR199501353A2 (tr) 1996-06-21
DE69516534D1 (de) 2000-05-31
NO972046D0 (no) 1997-05-02
CZ288322B6 (en) 2001-05-16
GR3033956T3 (en) 2000-11-30
IL115862A0 (en) 1996-01-31
AU690756B2 (en) 1998-04-30
CA2204380A1 (en) 1996-05-17
NO972046L (no) 1997-05-02
ATE192166T1 (de) 2000-05-15
ITMI942238A1 (it) 1996-05-04
KR100426029B1 (ko) 2004-07-31
ZA959255B (en) 1996-05-29
DE69516534T2 (de) 2000-11-30
BR9509556A (pt) 1997-09-16
IL115862A (en) 2001-06-14
RU2160445C2 (ru) 2000-12-10
CN1166838A (zh) 1997-12-03
CZ131497A3 (en) 1997-12-17
ITMI942238A0 (it) 1994-11-04
PL319878A1 (en) 1997-09-01
JPH10508591A (ja) 1998-08-25
HUT76880A (en) 1997-12-29
WO1996014340A1 (en) 1996-05-17
DK0789716T3 (da) 2000-10-09
FI971879A0 (fi) 1997-05-02
IT1276860B1 (it) 1997-11-03
KR970707161A (ko) 1997-12-01
ES2147617T3 (es) 2000-09-16
FI971879L (fi) 1997-06-24

Similar Documents

Publication Publication Date Title
CA2040374A1 (en) Process for enhancing the resistance of aquatic animals to disease
ATE210127T1 (de) 6-substituierte mycophenolsäurederivate mit immun suppressiver wirkung
ATE242633T1 (de) Dialkylfumarate zur behandlung von autoimmunerkrankungen
ATE211467T1 (de) 4-amino-derivate der mycophenolsäure mit immun suppressiver wirkung
ES2164914T3 (es) Medicamentos de inmunoterapia que contienen anticuerpos que detectan especificamente el antigeno mhcii del paciente a tratar.
MX9603925A (es) Combinaciones de anticoagulantes y proteinas activas tromboliticamente, y usos de las mismas.
ATE517125T1 (de) ANTIKÖRPER GEGEN ßDEATH RECEPTOR 4ß (DR4) UND DEREN VERWENDUNGEN
GB2255093A (en) Hiv-1 core protein fragments
DE69738692D1 (de) LO-CD2a ANTIKÖRPER UND DESSEN VERWENDUNGEN ZUR HEM
DK0754229T3 (da) Afamin: et humant serum albumin-lignende protein
ATE234111T1 (de) Therapeutische verwendungen von bpi-protein produkten bei menschen mit durch trauma verursachter blutung
NZ505834A (en) Compositions containing polypeptides isolated from mycobacterium vaccae and methods for their use
DE69634499D1 (de) Verwendungsmethoden von einkernigen phagozyten zur förderung der axonalen regeneration
FI953093A0 (fi) Menetelmiä, joilla voidaan havaita ja hoitaa yksilöitä, joilla on epänormaaleja soluja, jotka ekspressoivat HLA-A2/tyrosinaasi-peptidiantigeenejä
KR890700353A (ko) 면역독소의 면역억제 기저 사람치료법
PT768886E (pt) Efeitos de revestimento endotelial e tratamento de desordens vasospasticas
BR0109928A (pt) Uso de um herpes vìrus atenuado, e, método para estimular uma resposta imune em um indivìduo humano ou animal, ou para tratar ou prevenir uma infecção patogênica ou câncer em um indivìduo humano ou animal
IL114458A0 (en) Therapeutic preparations for treatment of T cell mediated diseases
AR002243A1 (es) Anticuerpos contra proteinas alogenicas y xenogenicas, su uso en diagnostico y terapia y metodos para la determinacion de los mismos.
DE69928523D1 (de) Verotoxin b untereinheit zur immunisierunug
PT782630E (pt) Gene da doenca poliquistica do rim
Raffel Bacterial hypersensitivity
ATE249243T1 (de) Biotinylierter antikörper mit verminderter positiver nettoladung und toxin, medikament oder chelat
Imai et al. Effects of dibutyryl cyclic AMP on hyaluronan and proteoglycan synthesis by retroocular tissue fibroblasts in culture
BRPI0409321A (pt) antìgeno hìbrido, competição e método para induzir uma resposta imune para um agente infeccioso ou antìgeno de tumor, método para tratar uma doença infecciosa ou cáncer, e, peptìdeo

Legal Events

Date Code Title Description
FG Grant or registration
MM Annulment or lapse due to non-payment of fees